TapewireFind a company

person · Reporting owner

LOUMEAU ERIC J

Disclosed activity across 2 companies

Tapewire entity
66472
SEC CIK
0001239648

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ANAPTYSBIO, INCANAB · Entity 4640CHIEF LEGAL OFFICERFebruary 11, 2026February 13, 2026
OTONOMY, INC.OTIC · Entity 116495GC & Chief Compliance OfficerFebruary 01, 2018February 05, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ANAPTYSBIO, INC

Report date February 11, 2026 · Filed February 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect12,835 Ending reported balance After 2026-02-11 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-11 · Exercise / conversion · Acquired 10,000 · Balance 22,835

Row 2 · 2026-02-11 · Sale · Disposed 10,000 · Balance 12,835

F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.

Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.70 · Expires 2031-02-09Direct35,000 Reported balance After 2026-02-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-11 · Exercise / conversion · Disposed 10,000 · Balance 35,000

F2: The stock option is fully vested.

F3: In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.

F2: The stock option is fully vested.

F3: In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.

OTONOMY, INC.

Report date February 01, 2018 · Filed February 05, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.80 · Expires 2028-01-31Direct110,000 Reported balance After 2018-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2018-02-01 · Grant · Acquired 110,000 · Balance 110,000

F1: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter.

F2: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms.

Filing footnotes · ownership attribution and instrument terms

F1: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter.

F2: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 16, 2024 Filed Feb 21, 2024 17:38 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 5,000 $25.00 $125,000.00
Disclosure

SEC source: 0001415889-24-004666 · form4-02212024_100259.xml · nonDerivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,240

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated September 15, 2023.

Read SEC document
February 16, 2024 Filed Feb 21, 2024 17:38 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 5,000 $14.02 $70,100.00
Disclosure

SEC source: 0001415889-24-004666 · form4-02212024_100259.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · CHIEF LEGAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
January 08, 2024 Filed Jan 9, 2024 19:07 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 2,305 $21.81 $50,272.05
Disclosure

SEC source: 0001209191-24-001279 · doc4.xml · nonDerivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,240

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
January 06, 2024 Filed Jan 9, 2024 19:07 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionRestricted Stock Unit · Derivative 5,545 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001279 · doc4.xml · derivative · entry 3

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,635

Underlying: Common Stock · 5,545 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 06, 2024 Filed Jan 9, 2024 19:07 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 5,545 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001279 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,545

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 16:55 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantRestricted Stock Unit · Derivative 29,150 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-001047 · doc4.xml · derivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,150

Underlying: Common Stock · 29,150 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 03, 2024 Filed Jan 5, 2024 16:55 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 79,780 $0.00 Strike: $21.19 $0.00
Disclosure

SEC source: 0001209191-24-001047 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,780

Underlying: Common Stock · 79,780 shares

Expires 2034-01-02

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 16:03 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 882 $14.19 $12,515.58
Disclosure

SEC source: 0001209191-23-056638 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated September 29, 2022, as amended February 21, 2023.

F2 · shares: The shares sold represent 882 shares purchased pursuant to the Company's ESPP at 85% of the lesser of the closing price of the Issuer's Common Stock on November 16, 2022 and the closing price of May 15, 2023.

Read SEC document
September 18, 2023 Filed Sep 18, 2023 18:13 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 3,895 $19.32 $75,232.31
Disclosure

SEC source: 0001209191-23-049809 · doc4.xml · nonDerivative · entry 3

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 882

F4 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.135 to $19.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 18:13 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionRestricted Stock Unit · Derivative 6,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-049809 · doc4.xml · derivative · entry 4

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F6 · derivative.exercise_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F6 · derivative.expiration_date: 50% of the total restricted stock units vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 18:13 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 2,105 $19.48 $41,005.40
Disclosure

SEC source: 0001209191-23-049809 · doc4.xml · nonDerivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,777

F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 18:13 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 6,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-049809 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,882

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · balance_after: Reflects the acquisition of 882 shares acquired under the Company's ESPP.

Read SEC document
January 06, 2023 Filed Jan 10, 2023 19:08 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantRestricted Stock Unit · Derivative 22,180 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-002881 · doc4.xml · derivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,180

Underlying: Common Stock · 22,180 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
January 06, 2023 Filed Jan 10, 2023 19:08 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 60,530 $0.00 Strike: $23.23 $0.00
Disclosure

SEC source: 0001209191-23-002881 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,530

Underlying: Common Stock · 60,530 shares

Expires 2033-01-05

F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Read SEC document
September 14, 2022 Filed Sep 16, 2022 17:07 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantRestricted Stock Unit · Derivative 12,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-050351 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents a one-time retention grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F2 · derivative.expiration_date: 50% of the total RSUs vest on September 14, 2023 and September 14, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · balance_after: In addition to the remaining options to purchase 12,000 shares of common stock as set forth in Table II above, the Reporting Person also holds an additional options to purchase up to an aggregate of 308,000 shares of common stock, which options vest according to their terms.

Read SEC document
August 08, 2022 Filed Aug 9, 2022 18:03 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 523 $25.00 $13,075.00
Disclosure

SEC source: 0001209191-22-045061 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares sold represent 523 shares purchased pursuant to the Company's ESPP at 85% of the lesser of the closing price of the Issuer's Common Stock on November 15, 2021.

Read SEC document
June 23, 2022 Filed Jun 27, 2022 19:04 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $29.70 $0.00
Disclosure

SEC source: 0001209191-22-039532 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2031-02-09

F1 · derivative.exercise_date: On February 10, 2021, the reporting person was granted a performance-based option to purchase 10,000 shares of the Issuer's common stock, subject to the achievement of certain corporate performance criteria and the reporting person's continued service to the Issuer upon achievement thereof. The performance criteria were achieved on the date in Column 3, resulting in the vesting of the entire award.

F2 · balance_after: In addition to the remaining options to purchase 10,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 298,000 shares of common stock, which options vest according to their terms, and (ii) 523 shares of common stock held directly.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 17:22 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 2,500 $0.00 Strike: $14.02 $0.00
Disclosure

SEC source: 0001209191-22-036020 · doc4.xml · derivative · entry 3

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,000

Underlying: Common Stock · 2,500 shares

Expires 2029-12-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F3 · balance_after: In addition to the remaining options to purchase 83,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 215,000 shares of common stock, which options vest according to their terms.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 17:22 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 2,500 $24.00 $60,000.00
Disclosure

SEC source: 0001209191-22-036020 · doc4.xml · nonDerivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 17:22 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 2,500 $14.02 $35,050.00
Disclosure

SEC source: 0001209191-22-036020 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,023

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 18, 2022 Filed May 20, 2022 16:42 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 1,146 $20.50 $23,493.00
Disclosure

SEC source: 0001209191-22-031028 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · shares: The shares sold represent 1,146 shares purchased pursuant to the Company's ESPP at 85% of the lesser of the closing price of the Issuer's Common Stock on May 13, 2022 and November 16, 2022.

Read SEC document
February 10, 2022 Filed Feb 14, 2022 16:47 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 70,000 $0.00 Strike: $30.44 $0.00
Disclosure

SEC source: 0001209191-22-009335 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2032-02-09

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2023, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F2 · balance_after: In addition to the remaining options to purchase 70,000 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 230,500 shares of common stock, which options vest according to their terms, and (ii) 523 shares of common stock held directly.

Read SEC document
November 15, 2021 Filed Nov 17, 2021 17:18 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantCommon Stock 523 $22.03 $11,521.69
Disclosure

SEC source: 0001209191-21-065168 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 523

F1 · shares: Represents shares of Common Stock acquired pursuant to the Issuer's Employee Stock Purchase Plan ("ESPP"), for the purchase period through November 15, 2021. In accordance with the ESPP, these shares were purchased at 85% of the lesser of the closing price of the Issuer's Common Stock on May 17, 2021 and November 15, 2021.

F2 · balance_after: In addition to the reporting person's common stock directly held as set forth in Table I above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 230,500 shares of common stock, which options vest according to their terms.

Read SEC document
November 04, 2021 Filed Nov 5, 2021 18:23 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 2,500 $0.00 Strike: $20.16 $0.00
Disclosure

SEC source: 0001209191-21-063260 · doc4.xml · derivative · entry 5

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 2,500 shares

Expires 2030-07-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F3 · balance_after: In addition to the remaining options to purchase 93,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 137,500 shares of common stock, which options vest according to their terms.

Read SEC document
November 04, 2021 Filed Nov 5, 2021 18:23 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 2,500 $0.00 Strike: $14.02 $0.00
Disclosure

SEC source: 0001209191-21-063260 · doc4.xml · derivative · entry 4

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,500

Underlying: Common Stock · 2,500 shares

Expires 2029-12-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F3 · balance_after: In addition to the remaining options to purchase 93,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 137,500 shares of common stock, which options vest according to their terms.

Read SEC document
November 04, 2021 Filed Nov 5, 2021 18:23 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 5,000 $35.00 $175,000.00
Disclosure

SEC source: 0001209191-21-063260 · doc4.xml · nonDerivative · entry 3

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

Read SEC document
November 04, 2021 Filed Nov 5, 2021 18:23 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 2,500 $20.16 $50,400.00
Disclosure

SEC source: 0001209191-21-063260 · doc4.xml · nonDerivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 04, 2021 Filed Nov 5, 2021 18:23 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 2,500 $14.02 $35,050.00
Disclosure

SEC source: 0001209191-21-063260 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 12, 2021 Filed Feb 12, 2021 21:28 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $14.02 $0.00
Disclosure

SEC source: 0001209191-21-010517 · doc4.xml · derivative · entry 4

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,000

Underlying: Common Stock · 10,000 shares

Expires 2029-12-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F4 · balance_after: In addition to the remaining option to purchase 88,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 147,500 shares of common stock, which options vest according to their terms.

Read SEC document
February 12, 2021 Filed Feb 12, 2021 21:28 UTC ANAPTYSBIO, INC ANAB · Entity 4640 SaleCommon Stock 10,000 $35.00 $350,000.00
Disclosure

SEC source: 0001209191-21-010517 · doc4.xml · nonDerivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transaction reported on this Form 4 were effected pursuant to a Rule 105b-1 trading plan adopted by the reporting person.

Read SEC document
February 12, 2021 Filed Feb 12, 2021 21:28 UTC ANAPTYSBIO, INC ANAB · Entity 4640 Exercise / conversionCommon Stock 10,000 $14.02 $140,200.00
Disclosure

SEC source: 0001209191-21-010517 · doc4.xml · nonDerivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 10, 2021 Filed Feb 12, 2021 21:28 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (right to buy) · Derivative 45,000 $0.00 Strike: $29.70 $0.00
Disclosure

SEC source: 0001209191-21-010517 · doc4.xml · derivative · entry 3

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2031-02-09

F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Read SEC document
July 13, 2020 Filed Jul 15, 2020 17:06 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantEmployee Stock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $20.16 $0.00
Disclosure

SEC source: 0001209191-20-042506 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · COO, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-07-12

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on July 15, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Read SEC document
December 06, 2019 Filed Dec 10, 2019 17:40 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantEmployee Stock Option (Right to Buy) · Derivative 98,000 $0.00 Strike: $14.02 $0.00
Disclosure

SEC source: 0001209191-19-059924 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · General Counsel & Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,000

Underlying: Common Stock · 98,000 shares

Expires 2029-12-05

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.

Read SEC document
August 18, 2019 Filed Aug 20, 2019 17:04 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantEmployee Stock Option (Right to Buy) · Derivative 17,500 $0.00 Strike: $49.20 $0.00
Disclosure

SEC source: 0001209191-19-046820 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · General Counsel & Interim CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2029-08-17

F1 · derivative.exercise_date: The option vests over a 4 year period: 25% vest and become exercisable on August 18, 2020, after which 1/48th of the total shares vest and become exercisable monthly thereafter, subject to reporting person's continuous service through each vesting date.

Read SEC document
February 08, 2019 Filed Feb 11, 2019 17:30 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantEmployee Stock Option (Right to Buy) · Derivative 35,000 $0.00 Strike: $68.89 $0.00
Disclosure

SEC source: 0001209191-19-009028 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2029-02-07

F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

Read SEC document
August 06, 2018 Filed Aug 8, 2018 17:56 UTC ANAPTYSBIO, INC ANAB · Entity 4640 GrantStock Option (Right to Buy) · Derivative 40,000 $0.00 Strike: $78.18 $0.00
Disclosure

SEC source: 0001209191-18-045892 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2028-08-05

F1 · derivative.exercise_date: The option vests over a 4 year period: 25% vest and become exercisable on August 6, 2019, after which 1/48th of the total shares vest and become exercisable monthly thereafter, subject to reporting person's continuous service through each vesting date.

Read SEC document
February 01, 2018 Filed Feb 5, 2018 17:38 UTC OTONOMY, INC. OTIC · Entity 116495 GrantEmployee Stock Option (right to buy) · Derivative 110,000 $0.00 Strike: $5.80 $0.00
Disclosure

SEC source: 0001209191-18-007610 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2028-01-31

F1 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on February 1, 2019 and one forty-eighth (1/48) of the shares vest monthly thereafter.

F2 · balance_after: In addition to the options acquired as set forth in Table II, the Reporting Person currently holds options to purchase up to an aggregate of 146,665 shares of common stock, which options vest according to their terms.

Read SEC document
January 19, 2018 Filed Jan 23, 2018 17:34 UTC OTONOMY, INC. OTIC · Entity 116495 GrantEmployee Stock Option (right to buy) · Derivative 33,333 Not disclosed Strike: $5.68 Not disclosed
Disclosure

SEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 6

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,333

Underlying: Common Stock · 33,333 shares

Expires 2026-01-18

F6 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 50,000 shares of common stock granted to the Reporting Person on March 6, 2017. In exchange, the Reporting Person received an option grant for 33,333 shares of common stock with exercise price of $5.675 per share.

F9 · derivative.exercise_date: Of the 33,333 total shares subject to the option, 11,111 shares vest on January 19, 2019. Of the remaining 22,222 shares subject to the option, one-third (1/3) of these shares vest on January 19, 2019, and one thirty-sixth (1/36) of these shares vest monthly thereafter.

Read SEC document
January 19, 2018 Filed Jan 23, 2018 17:34 UTC OTONOMY, INC. OTIC · Entity 116495 GrantEmployee Stock Option (right to buy) · Derivative 46,666 Not disclosed Strike: $5.68 Not disclosed
Disclosure

SEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 5

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,666

Underlying: Common Stock · 46,666 shares

Expires 2026-01-18

F4 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 70,000 shares of common stock granted to the Reporting Person on March 1, 2016. In exchange, the Reporting Person received an option grant for 46,666 shares of common stock with exercise price of $5.675 per share.

F8 · derivative.exercise_date: Of the 46,666 total shares subject to the option, 27,222 shares vest on January 19, 2019. Of the remaining 19,444 shares subject to the option, one-third (1/3) of these shares vest on January 19, 2019, and one thirty-sixth (1/36) of these shares vest monthly thereafter.

Read SEC document
January 19, 2018 Filed Jan 23, 2018 17:34 UTC OTONOMY, INC. OTIC · Entity 116495 GrantEmployee Stock Option (right to buy) · Derivative 66,666 Not disclosed Strike: $5.68 Not disclosed
Disclosure

SEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 4

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,666

Underlying: Common Stock · 66,666 shares

Expires 2026-01-18

F2 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 100,000 shares of common stock granted to the Reporting Person on May 15, 2015. In exchange, the Reporting Person received an option grant for 66,666 shares of common stock with exercise price of $5.675 per share.

F7 · derivative.exercise_date: Of the 66,666 total shares subject to the option, 52,777 shares vest on January 19, 2019. Of the remaining 13,889 shares subject to the option, one-third (1/3) of these shares vest on January 19, 2019, and one thirty-sixth (1/36) of these shares vest monthly thereafter.

Read SEC document
January 19, 2018 Filed Jan 23, 2018 17:34 UTC OTONOMY, INC. OTIC · Entity 116495 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 50,000 Not disclosed Strike: $14.00 Not disclosed
Disclosure

SEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 3

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2027-03-05

F6 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 50,000 shares of common stock granted to the Reporting Person on March 6, 2017. In exchange, the Reporting Person received an option grant for 33,333 shares of common stock with exercise price of $5.675 per share.

F5 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on March 6, 2018 and one forty-eighth (1/48) of the shares vest monthly thereafter.

Read SEC document
January 19, 2018 Filed Jan 23, 2018 17:34 UTC OTONOMY, INC. OTIC · Entity 116495 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 70,000 Not disclosed Strike: $14.44 Not disclosed
Disclosure

SEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 70,000 shares

Expires 2026-02-28

F4 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 70,000 shares of common stock granted to the Reporting Person on March 1, 2016. In exchange, the Reporting Person received an option grant for 46,666 shares of common stock with exercise price of $5.675 per share.

F3 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on March 1, 2017 and one forty-eighth (1/48) of the shares vest monthly thereafter.

Read SEC document
January 19, 2018 Filed Jan 23, 2018 17:34 UTC OTONOMY, INC. OTIC · Entity 116495 Disposition to issuerEmployee Stock Option (right to buy) · Derivative 100,000 Not disclosed Strike: $31.59 Not disclosed
Disclosure

SEC source: 0001209191-18-004965 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2025-05-14

F2 · price: On January 19, 2018, in connection with the Issuer's option exchange program, the Issuer cancelled an option for 100,000 shares of common stock granted to the Reporting Person on May 15, 2015. In exchange, the Reporting Person received an option grant for 66,666 shares of common stock with exercise price of $5.675 per share.

F1 · derivative.exercise_date: One-fourth (1/4) of the total number of shares initially subject to the option vest on May 15, 2016, and one forty-eighth (1/48) of the shares vest monthly thereafter.

Read SEC document
June 26, 2017 Filed Jun 27, 2017 17:09 UTC OTONOMY, INC. OTIC · Entity 116495 SaleCommon Stock 1,206 $18.75 $22,612.50
Disclosure

SEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 6

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
June 23, 2017 Filed Jun 27, 2017 17:09 UTC OTONOMY, INC. OTIC · Entity 116495 SaleCommon Stock 2,316 $18.50 $42,846.00
Disclosure

SEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 5

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,206

F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

Read SEC document
June 01, 2017 Filed Jun 27, 2017 17:09 UTC OTONOMY, INC. OTIC · Entity 116495 GrantCommon Stock 1,206 $11.43 $13,784.58
Disclosure

SEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 4

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,522

F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan.

Read SEC document
March 06, 2017 Filed Mar 8, 2017 17:18 UTC OTONOMY, INC. OTIC · Entity 116495 GrantEmployee Stock Option (right to buy) · Derivative 50,000 $0.00 Strike: $14.00 $0.00
Disclosure

SEC source: 0001209191-17-019334 · doc4.xml · derivative · entry 1

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2027-03-06

F1 · derivative.exercise_date: One-fourth (1/4) of the shares subject to the option vest on March 6, 2018 and one forty-eighth (1/48) of the shares vest monthly thereafter.

F2 · balance_after: In addition to the option to purchase 50,000 shares of common stock as set forth on Table II, the Reporting Person currently holds options to purchase up to an aggregate of 170,000 shares of common stock, which options vest according to their terms.

Read SEC document
December 01, 2016 Filed Jun 27, 2017 17:09 UTC OTONOMY, INC. OTIC · Entity 116495 GrantCommon Stock 647 $13.05 $8,443.35
Disclosure

SEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 3

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,316

F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan.

Read SEC document
June 01, 2016 Filed Jun 27, 2017 17:09 UTC OTONOMY, INC. OTIC · Entity 116495 GrantCommon Stock 1,021 $13.13 $13,405.73
Disclosure

SEC source: 0001209191-17-041981 · doc4.xml · nonDerivative · entry 2

LOUMEAU ERIC J · CIK 0001239648 · GC & Chief Compliance Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,669

F1 · balance_after: Acquired pursuant to the Issuer's 2014 Employee Stock Purchase Plan.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.